Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-02-02
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 149
- Registration Number
- NCT00102817
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Use of Activated Recombinant FVII in Spinal Surgery
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-01-20
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT00102037
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Seattle, Washington, United States
INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4877
- Registration Number
- NCT00101751
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 293
- Registration Number
- NCT00097877
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Santurce, Puerto Rico
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-11-22
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 230
- Registration Number
- NCT00097279
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 299
- Registration Number
- NCT00097071
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 324
- Registration Number
- NCT00097084
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Ängelholm, Sweden
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2004-11-05
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 513
- Registration Number
- NCT00095446
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Princeton, New Jersey, United States
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 447
- Registration Number
- NCT00095082
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-10-24
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 378
- Registration Number
- NCT00071448
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Madison, Wisconsin, United States
© Copyright 2024. All Rights Reserved by MedPath